This pharmaceutical blue chip could be ready to rally higher.While the COVID-19 pandemic is an increasingly distant memory for most investors, Pfizer (PFE -0.73%) has struggled to move past the overhang of record vaccine sales and earnings in 2021 and 2022. The stock is down about 53% from its all-time high as the market wonders whether the pharmaceutical giant can find its next blockbuster drug.The good news is that the company's latest results highlighted a growth rebound. Sales momentum from several rece ...